[go: up one dir, main page]

AU4870893A - Quaternary basic amides, method of preparing them and pharmaceutical compositions in which they are present - Google Patents

Quaternary basic amides, method of preparing them and pharmaceutical compositions in which they are present

Info

Publication number
AU4870893A
AU4870893A AU48708/93A AU4870893A AU4870893A AU 4870893 A AU4870893 A AU 4870893A AU 48708/93 A AU48708/93 A AU 48708/93A AU 4870893 A AU4870893 A AU 4870893A AU 4870893 A AU4870893 A AU 4870893A
Authority
AU
Australia
Prior art keywords
group
alkyl
preparing
omega
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU48708/93A
Other versions
AU674875B2 (en
Inventor
Xavier Emonds-Alt
Patrick Gueule
Vincenzo Proietto
Didier Van Broeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Elf Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elf Sanofi SA filed Critical Elf Sanofi SA
Publication of AU4870893A publication Critical patent/AU4870893A/en
Application granted granted Critical
Publication of AU674875B2 publication Critical patent/AU674875B2/en
Assigned to SANOFI reassignment SANOFI Request to Amend Deed and Register Assignors: ELF SANOFI
Assigned to SANOFI-SYNTHELABO reassignment SANOFI-SYNTHELABO Request to Amend Deed and Register Assignors: SANOFI
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS Request to Amend Deed and Register Assignors: SANOFI-SYNTHELABO
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to basic quaternary amides of formula <IMAGE> in which - Ar represents an optionally substituted mono-, di- or tricyclic heteroaromatic or aromatic group; - T represents a direct bond, a hydroxymethylene group, an alkoxymethylene group in which the alkoxy group is C1-C4 or a C1-C5 alkylene group; - Ar' represents a phenyl which is unsubstituted or substituted one or a number of times, a thienyl, a benzothienyl, a naphthyl or an indolyl; - R represents hydrogen, a C1-C4 alkyl, an omega -(C1-C4)alkoxy(C2-C4)alkyl or an omega -(C1-C4)alkanoyloxy(C2-C 4)alkyl, - Q represents hydrogen; - or else Q and R, together, form a 1,2-ethylene, 1,3-propylene or 1,4-butylene group; - Am<(+)> represents the radical <IMAGE> in which X1, X2 and X3, together and with the nitrogen atom to which they are bonded, form an azabicyclic or azatricyclic system optionally substituted by a phenyl group; - A<(-)> is a pharmaceutically acceptable anion. These compounds are useful in the preparation of medicaments intended for the treatment of pathologies involving the tachykinin system.
AU48708/93A 1992-09-30 1993-09-30 Quaternary basic amides, method of preparing them and pharmaceutical compositions in which they are present Ceased AU674875B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9212083A FR2696178B1 (en) 1992-09-30 1992-09-30 Quaternary basic amides, process for their preparation and pharmaceutical compositions containing them.
FR9212083 1992-09-30

Publications (2)

Publication Number Publication Date
AU4870893A true AU4870893A (en) 1994-04-14
AU674875B2 AU674875B2 (en) 1997-01-16

Family

ID=9434374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48708/93A Ceased AU674875B2 (en) 1992-09-30 1993-09-30 Quaternary basic amides, method of preparing them and pharmaceutical compositions in which they are present

Country Status (27)

Country Link
EP (1) EP0591040B1 (en)
JP (2) JP2857041B2 (en)
KR (1) KR100279084B1 (en)
CN (1) CN1036652C (en)
AT (1) ATE176469T1 (en)
AU (1) AU674875B2 (en)
BR (1) BR9303982A (en)
CA (1) CA2107432C (en)
CZ (1) CZ287272B6 (en)
DE (1) DE69323375T2 (en)
DK (1) DK0591040T3 (en)
ES (1) ES2130238T3 (en)
FI (1) FI114474B (en)
FR (1) FR2696178B1 (en)
GR (1) GR3030000T3 (en)
HU (2) HU215848B (en)
IL (1) IL107158A0 (en)
MX (1) MX9306024A (en)
MY (1) MY108881A (en)
NO (1) NO304888B1 (en)
NZ (1) NZ248821A (en)
OA (1) OA09869A (en)
RU (1) RU2120436C1 (en)
SG (1) SG47807A1 (en)
SI (1) SI9300513B (en)
TW (1) TW242625B (en)
ZA (1) ZA937276B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583134A (en) * 1992-09-30 1996-12-10 Sanofi 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which they are present
FR2717802B1 (en) * 1994-03-25 1996-06-21 Sanofi Sa New aromatic compounds, process for their preparation and pharmaceutical compositions containing them.
FR2717804B1 (en) * 1994-03-25 1996-06-21 Sanofi Sa Salts of substituted nitrogen heteroaromatic compounds, process for their preparation and pharmaceutical compositions containing them.
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
PL180866B1 (en) 1994-07-12 2001-04-30 Lilly Co Eli Heterocyclic antagonists of tachykinin receptors
FR2725900B1 (en) * 1994-10-21 1997-07-18 Sanofi Sa USE OF NK1 RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS WITH CARDIOREGULATORY ACTION
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
EP0714891A1 (en) * 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists
FR2751654B1 (en) * 1996-07-26 1998-10-23 Sanofi Sa SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2729954B1 (en) * 1995-01-30 1997-08-01 Sanofi Sa SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2729951B1 (en) * 1995-01-30 1997-04-18 Sanofi Sa NOVEL HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2729952B1 (en) * 1995-01-30 1997-04-18 Sanofi Sa SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
DE69626123T2 (en) * 1995-06-06 2003-10-09 Schering Corp., Kenilworth SUBSTITUTED BENZO-CONDENSED HETEROCYCLES AS NEUROKININ ANTAGONISTS
FR2745811B1 (en) 1996-03-07 1998-05-22 Sanofi Sa DISSUBSTITUTED GLUTARIMIDE PROCESS FOR ITS PREPARATION, AND ITS USE
CA2255910A1 (en) * 1996-05-24 1997-11-27 Mitchell Irvin Steinberg Methods of treating hypertension
US5691362A (en) * 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
GB9617730D0 (en) * 1996-08-23 1996-10-02 Pfizer Ltd Quarternary ammonium compounds
FR2759584B1 (en) * 1997-02-17 1999-06-11 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR THE ORAL ADMINISTRATION OF HETEROCYCLIC COMPOUNDS IN QUATERNARY AMMONIUM FORM
FR2759585B1 (en) 1997-02-17 1999-06-11 Sanofi Sa PHARMACEUTICAL FORMULATIONS PRESENTED IN A DRY FORM FOR THE ORAL ADMINISTRATION OF A CYCLIC QUATERNARY AMMONIUM COMPOUND
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
GB9712882D0 (en) * 1997-06-18 1997-08-20 Pfizer Ltd Quaternary ammonium compounds
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
AU737019B2 (en) * 1997-08-04 2001-08-09 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
GB9927125D0 (en) 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
EP1754701A4 (en) * 2004-02-25 2007-10-03 Sankyo Co Sulfonyloxy derivatives
JP2008534504A (en) 2005-03-22 2008-08-28 アゼヴァン ファーマスーティカルズ,インコーポレイテッド Β-Lactamyl alkanoic acid for treating premenstrual disorders
SI1910346T1 (en) 2005-07-19 2019-08-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
JP2010516731A (en) 2007-01-24 2010-05-20 グラクソ グループ リミテッド Pharmaceutical composition comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-1-yl) -benzyl]-(2S-phenyl-piperidin-3S-yl) -amine
UA105182C2 (en) 2008-07-03 2014-04-25 Ньюрексон, Інк. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
RU2623209C9 (en) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Method for ptsd treatment
FI3122743T3 (en) 2014-03-28 2023-03-02 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
CA3047023C (en) * 2016-12-14 2022-05-31 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
US11628160B2 (en) 2017-09-15 2023-04-18 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2666185B1 (en) * 1990-08-21 1992-12-04 Sgs Thomson Microelectronics INTERPOLATION ANALOG / DIGITAL CONVERTER.
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
SI9300513B (en) 2002-02-28
HU211889A9 (en) 1995-12-28
FI114474B (en) 2004-10-29
IL107158A0 (en) 1993-12-28
HU215848B (en) 1999-04-28
SI9300513A (en) 1994-06-30
JPH10175976A (en) 1998-06-30
EP0591040A1 (en) 1994-04-06
CZ203593A3 (en) 1994-04-13
EP0591040B1 (en) 1999-02-03
CA2107432A1 (en) 1994-03-31
CN1036652C (en) 1997-12-10
FI934273A (en) 1994-03-31
AU674875B2 (en) 1997-01-16
JPH06211850A (en) 1994-08-02
SG47807A1 (en) 1998-04-17
NO304888B1 (en) 1999-03-01
NO933481L (en) 1994-04-05
HUT65759A (en) 1994-07-28
RU2120436C1 (en) 1998-10-20
NO933481D0 (en) 1993-09-29
MY108881A (en) 1996-11-30
ZA937276B (en) 1994-04-25
FR2696178B1 (en) 1994-12-30
KR100279084B1 (en) 2001-01-15
DE69323375D1 (en) 1999-03-18
GR3030000T3 (en) 1999-07-30
JP2857041B2 (en) 1999-02-10
DK0591040T3 (en) 1999-09-20
DE69323375T2 (en) 1999-06-24
BR9303982A (en) 1994-10-25
ES2130238T3 (en) 1999-07-01
MX9306024A (en) 1994-03-31
FR2696178A1 (en) 1994-04-01
OA09869A (en) 1994-08-15
ATE176469T1 (en) 1999-02-15
CA2107432C (en) 2000-04-04
CN1088582A (en) 1994-06-29
TW242625B (en) 1995-03-11
JP3243212B2 (en) 2002-01-07
HU9302770D0 (en) 1993-12-28
FI934273A0 (en) 1993-09-29
KR940007026A (en) 1994-04-26
CZ287272B6 (en) 2000-10-11
NZ248821A (en) 1995-10-26

Similar Documents

Publication Publication Date Title
AU4870893A (en) Quaternary basic amides, method of preparing them and pharmaceutical compositions in which they are present
RU93055131A (en) QUARTERLY AMIDES OF BASIC CHARACTER, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITION
WO1990004918A3 (en) Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GR3020139T3 (en) Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
EP0389282A3 (en) Xanthinederivatives, process for their preparation and their pharmaceutical use
FR2613624B1 (en) ORAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION FOR REDUCING THE EFFECTS OF B-LACTAMINES
ZA898678B (en) Compositions and compounds
IT1150213B (en) BIOAVAILABLE IRON DERIVATIVES FREE FROM GASTROLESIVITY, PREPARATION PROCEDURE AND RELATED PHARMACEUTICAL COMPOSITIONS
DE3269309D1 (en) Pyrrolo(2,3-d)carbazole derivatives, preparation thereof and their therapeutical use
IE872578L (en) Antigestagen compositions
IL90244A0 (en) Peptide-drug compositions containing alpha-aminoboronic acid derivatives
IL106080A (en) Pharmaceutical compositions containing amidinoalkane-1, 1-bisphosphonic acids and some such novel compounds
AU2215483A (en) Pharmaceutical n-alkyl-(3 or 4)-piperidinyl benzoate derivatives
ES8201151A1 (en) 5-Sulfamoyl-orthanilic acids, processes for their preparation, therapeutic compositions containing them and the compounds for use in therapy.
ZA922252B (en) Bis-Naphthalimides containing amino acid derived linkers as anticancer agents
HU895452D0 (en) Process for the preparation of pharmaceutical compositions of new dose form

Legal Events

Date Code Title Description
HB Alteration of name in register

Free format text: SANOFI-SYNTHELABO